l 30

L 30 is a blocker of the sodium channel.

PD-1/PD-L1-IN-30 is a PD-1/PD-L1 binding inhibitor, with an IC 50 value of 0.018 μM. PD-1/PD-L1-IN-30 can be used for research of cancers and other related diseases .

Anti-CD30L Antibody is an antibody targeting CD30L and can be used for immunology research.

exo-α-Arabinosidase, Rhodanobacter ginsenosidimutans Gsoil 3054T (EC.3.2.1.55), is a glycoside hydrolase enzyme.

PEG300 (Polyethylene glycol 300) is a polymer formed from repeating units of ethylene glycol that is water soluble, low immunogenicity, and biocompatible. PEG300 is a neutral polymer with a molecular weight of 300.

Moxidectin (CL301423) is an anthelmintic drug which kills parasitic worms, and is used for the prevention and control of heartworm and intestinal worms. It can be found in treatments prescribed for animals such as dogs, cats, horses, cattle and sheep. Application methods for moxidectin vary by treatment, and include oral, topical, and injectable solutions. Cydectin Pour On is a trade name for a formulation for use on cattle and red deer.

Besifloxacin Hydrochloride (BOL-303224-A) is a fourth-generation fluoroquinolone antibiotic.

Levoleucovorin Calcium (CL307782), a calcium salt of the folinic acid, is used in cancer chemotherapy as an adjuvant.

Homo-PROTAC pVHL30 degrader 1 is a potent PROTAC-based degrader of pVHL30.

ML303 is an antagonist of pyrazolopyridine influenza virus nonstructural protein 1 (NS1) (IC90 : 155 nM).

(S)-Mapracorat is a selective and less active agonist of the glucocorticoid receptor.

Mapracorat (ZK-245186, BOL-303242X) is a selective glucocorticoid receptor agonist commonly used as an anti-inflammatory agent for atopic dermatitis, post-cataract surgery inflammation, and allergic conjunctivitis.

BAL30072 shows MIC90 values of 4 μg/mL for MDR Acinetobacter spp. and 8 μg/mL for MDR P. aeruginosa, respectively[1][2]. BAL-30072, a siderophore sulfactam, is a monocyclic beta-lactam antibiotic, with activity against multiresistant gram-negative bacilli

Rociletinib hydrobromide is an orally delivered inhibitor of the mutant form of EGFR kinase (Kis: 21.5 nM and 303.3 nM for EGFR L858R/T790M and EGFR WT).

ML307 is a potent, first-in-class inhibitor of Ubc13 enzymatic activity, with an IC50 of 781 nM. It shows potential for use in immunomodulation and inflammation research.

ML301 is a small molecule G protein agonist. It can be inhibited by SR142948A, with an IC50 of approximately 63 nM. Additionally, ML301 exhibits the ability to fully compete for binding with [^125I-NT].

Rociletinib (CNX-419) is an orally available small molecule, irreversible inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity.

BMS-354326 is a bio-active chemical.

ML-309 is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1). It reversibly and selective inhibits IDH1R132H over wild-type IDH1 (IC50s = 96 and 36,500 nM, respectively). ML-309 reduces 2-hydroxyglutarate production in U87 MG glioblastoma cells (EC50 = 55 nM).

CPL304110 is an orally active, selective and potent inhibitor of the fibroblast growth factor receptor FGFR (1-3), acting on FGFR1 (IC50: 0.75 nM), FGFR2 (IC50: 0.5 nM), FGFR3 (IC50: 3.05 nM).

PP2 Analog is an analog of PP2. It also acts as a protein trafficking modulator.

Licofelone (ML-3000) is a dual COX/LOX inhibitor potentially for treating osteoarthritis, acting as both an analgesic and anti-inflammatory. By inhibiting 5-LOX, it may reduce the gastrointestinal toxicity associated with other non-steroidal anti-inflammatory drugs, which only inhibit COX (cyclooxygenase).

CEP-11981 is an orally active TIE2/pan-VEGFR inhibitor with broad tyrosine kinase inhibitory activity, exhibiting antitumour and anti-angiogenic effects, and is applicable for the treatment of refractory solid tumours.

Difenamizole HCl is the salt form of Difenamizole, a non-steroidal anti-inflammatory drug (NSAID) and analgesic of the pyrazolone group related to metamizole. It has monoaminergic properties, including inhibition of monoamine oxidase, augmentation of pargyline-induced elevation of striatal dopamine levels, inhibition of K+-induced striatal dopamine release, and inhibition of the reuptake of dopamine.